Articles Tagged With: ventilator-associated
-
Prophylactic Probiotics Do Not Reduce the Risk for Developing Ventilator-Associated Pneumonia
A multicenter, randomized, placebo-controlled clinical trial revealed the use of prophylactic probiotics did not reduce the risk for developing ventilator-associated pneumonia or improve other outcomes for intensive care unit patients, compared to placebo.
-
Antibiotic Therapy to Reduce the Incidence of Ventilator-Associated Pneumonia After Cardiac Arrest
In this prospective, randomized trial, intravenous amoxicillin-clavulanate (dosed three times daily and given for two days) administered to patients admitted with out-of-hospital cardiac arrest due to a shockable rhythm reduced the incidence of early ventilator-associated pneumonia.
-
Antibiotic Therapy to Reduce the Incidence of Ventilator-Associated Pneumonia After Cardiac Arrest
In this prospective, randomized trial, intravenous amoxicillin-clavulanate (dosed three times daily and given for two days) administered to patients admitted with out-of-hospital cardiac arrest due to a shockable rhythm reduced the incidence of early ventilator-associated pneumonia.
-
REPROVE: Ceftazidime-avibactam vs. Meropenem in Hospital-acquired Pneumonia
Ceftazidime-avibactam therapy was non-inferior to meropenem treatment in a double-blind, randomized trial that included patients with nosocomial pneumonia, including those with ventilator-associated pneumonia.
-
Ventilator-associated Pneumonia with Minimal Ventilatory Requirements — Discontinuing Antibiotics After Three Days
Discontinuation of empiric antibiotic therapy given for treatment of presumed ventilator-associated pneumonia can be discontinued safely after three days in patients with minimal ventilator requirements.